Mitizodone Phosphate not checked
Sunshine Lake Pharma Co., Ltd. · HEC113995PA•H2O
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Mitizodone Phosphate tablets will be administered with food.”In the company’s words, NCT04984512 on ClinicalTrials.gov
- Tested for
- Depressive Disorder, Major
- Main trialPhase 2/3
- “This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.”In the company’s words, NCT04984512 on ClinicalTrials.gov
- Other names
- HEC113995PA•H2O
Other drugs for Depressive Disorder, Major
- SeltorexantJanssen Research & Development, LLC · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- OsavampatorNeurocrine Biosciences · Phase 3
- DT120Definium Therapeutics US, Inc. · Phase 3
Coming up1
- Jul 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Jul 2027 | The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder | |
| Phase 1Completed | 11 Dec 2019 | The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026